People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Pharmaceuticals, Biotechnology, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CEBIX Inc | — | Pharmaceuticals | Series B | $76.3M | $1.1B | 2012 |
| Dauntless 1, Inc. | — | Pharmaceuticals | Series A | $15.0M | $247.8M | 2016 |
| Altair Therapeutics, Inc. | — | Biotechnology | Series A | $6.5M | $233.8M | 2009 |
| Dauntless 2, Inc. | — | Pharmaceuticals | Series A | $6.1M | $187.5M | 2016 |
| Medsense Health, Inc. | — | Healthtech | Series A | $5.5M | $24.0M | 2024 |
Joel Martin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joel Martin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Powell | 2 | 14 |
| David Kabakoff | 2 | 7 |
| Mark Bakken | 1 | 24 |
| James I. Healy | 1 | 7 |
| Ivor Royston | 1 | 7 |
| Jason Brown | 1 | 7 |
| Kim Kamdar | 1 | 6 |
| Pratik Shah | 1 | 5 |
| David Shapiro | 1 | 4 |
| Lars G. Ekman | 1 | 3 |
| Michael Powell, Ph.D. | 1 | 2 |
| Nina G. Kjellson | 1 | 2 |
| William R. Rohn | 1 | 2 |
| NICOLE DEBERG | 1 | 1 |
| David G. Kabakoff | 1 | 1 |
| William G. Rohn | 1 | 1 |
| Pratik G. Shah | 1 | 1 |
| Pratik R. Shah | 1 | 1 |
| Nina I. Kjellson | 1 | 1 |
| John R. Wahren | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.